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A B S T R A C T
Colon cancer is a serious malignant type of cancer in the world. Acquisition of multi-drug resistance (MDR)
during chemotherapy is still a controversial challenge during cancer treatment. Accordingly, detection of safe
and impressive MDR-reversing targets such as microRNAs (miRNAs/miRs) can play critical role in cancer
treatment. Here, the functional effects of miR-29a in chemo-resistant colon cancer cells is scrutinized. The effect
of doxorubicin (DOX) on cell proliferation after miR-29a transfection has been evaluated using MTT assay in
HT29 and HT29/DOX cells. Rhodamine123 (Rh123) assay is used to identify the activity of common drug efflux
through membrane transporters P-glycoprotein (P-gp). P-gp and PTEN mRNA/protein expression levels were
measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and Western blot analyses.
Flow cytometry was employed to the investigation of apoptosis. ANOVA followed by Bonferroni's and Sidak's
tests were used to compare the data from different groups. Thus, it was shown that miRNA-29a overexpression
considerably inhibited the HT29/DOX viability. miR-29a significantly down-regulated P-gp expression and ac-
tivity in HT29/DOX cells and declined drug resistance through elevation of intracellular DOX. Furthermore,
upon miRNA-29a transfection, PTEN expression could be restored in resistant cells. These results have indicated
that miR-29a target PTEN ultimately P-gp, which is downstream of PTEN, inhibit drug resistance, proliferation,
and apoptosis through PI3K/Akt pathway. As a result, miR-29a overexpression is led to enhance the sensitivity of
HT29/DOX cells to DOX-treatment by targeting P-gp. MiR-29a might proffer a novel promising candidate for
colon cancer therapeutics during chemotherapy.
1. Introduction
Colon cancer is one of the five most causing of cancer-related deaths
worldwide in both sex (Coronel-Hernández et al., 2019). Whereby, the
complex pathophysiologic mechanisms result in colon cancer, and de-
spite improving surgical and adjuvant chemotherapy approaches, colon
cancer is still a controversial challenge in public health (Liu et al.,
2019). Despite signs of progress in chemotherapy against cancer, many
of these chemotherapeutic agents developed resistance towards the
cancer cells. This phenomenon, well-known as multidrug resistance
(MDR), remains a big pending to positive treatment outcomes in most
cancers (Nanayakkara et al., 2018). DOX is one of the most commonly
used chemotherapeutic agents, which particularly in advanced or me-
tastasis cancer patients. Mechanically, DOX represses topoisomerase II
(Top II) and intercalates directly to DNA double-strand, finally, re-
sulting in the intervention of gene transcription (Lage et al., 2006). In
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this regard, DOX-resistance is one of the pivotal leads of chemotherapy
failure in the treatment of advanced colon cancer (Yang et al., 2015).
Many relevant mechanisms for MDR have been described and dis-
cussed, among which of the importance of these mechanisms is the
overexpression of the ATP-binding cassette (ABC) transporter proteins,
which regulate the intracellular concentrations of cytotoxic agents
(Majidinia et al., 2017; Yousefi et al., 2017; Shafiei-Irannejad et al.,
2018). These pumps troughs decrease the accumulation of anticancer
drugs to sub-therapeutic levels in cells, therefore result in mitigating or
abolishing chemotherapy efficacy (Katayama et al., 2014). In this re-
gard, human P-170 glycoprotein (P-gp/ABCB1) is encoded by MDR1
gene, located on chromosome 7q2, which is dominant members of ABC
transporters. In cancer cells, overexpression of P-gp is a common oc-
currence seen with resistant phenotype, which leads to pumps out
various anticancer drugs, including anthracyclines (such as DOX), vinca
alkaloids, epipodophyllotoxins, taxanes, and xenobiotics. Indeed, P-gp
expression in tumor cells awards MDR to these anticancer drugs
(Katayama et al., 2014; Yousefi et al., 2017, Teng and Chen, 2019).
For overcoming this scenario, recent cancer therapy approaches are
focusing on targeting the mediators, which inhibit specific pathways
involved of MDR in these cells (Yousefi et al., 2017). In this regard,
phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is
a tumor suppressor gene, which is located at 10q23.31. PTEN is a
multifunctional protein provided phosphatase activity on protein sub-
strates including FAK, SHC, IRS1, Dvl2, PTK6, and PIP3 (Kotelevets
et al., 2018). Deficiency or inactivation of a single PTEN allele is ade-
quate to activation of the phosphoinositide 3-kinase (PI3K)/Akt/PKB
Fig. 1. The expression levels of miR-29a in HT29 and HT29/DOX cells
(*P < 0.05). Each point represents the mean ± S.D. (n = 3 independent
experiments).
Fig. 2. The sensitivity of HT29 and HT29/DOX cells to DOX. Cells were treated
with versatile concentrations of DOX. After 48 h of incubation, the viability
rates of the cells were measured using the MTT assay. Each point represents the
mean ± S.D. (n = 3 independent experiments; *P < 0.05 compared with
HT29/DOX cells).
Fig. 3. Effects of transfection of mir-29a and its inhibitor on DOX cytotoxicity.
Upon culture for 48 h after transfection with the miR-29a mimics, inhibitor or
control, (A) HT29 cells and (B) HT29/DOX cells were incubated with various
concentrations of DOX for 48 h; and the cell viability was defined by the MTT
assay. Each point represents the mean ± S.D. (n = 3 independent experi-
ments; *P < 0.05 compared with control).
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signaling pathway, which may result in colon cancer (Colakoglu et al.,
2008; Chen et al., 2019). PTEN inhibits the activation of PI3K/Akt
cascade through dephosphorylation of PIP3 to produce PIP2; whereby,
decrease cell proliferation, promote apoptosis, and revert invasiveness
(Kotelevets et al., 2018). Inversely, when PKB activated by suppression
PTEN leading to phosphorylation and activation in many proteins in-
cluding mTOR, IKK, Bad, caspase 9, GSK3β, and P-gp (Shen et al., 2016;
Chen et al., 2018a,b). Evidence illustrates that PTEN functions in a
dosage-dependent manner during tumor development. Non-coding
RNAs (ncRNAs) are critical regulators of PTEN, including microRNAs
(miRNAs/miRs) and lncRNAs, which specifically modulate the PTEN
expression (Li et al., 2018).
miRNAs are a family of RNAs with 18–22 nucleotides, which join to
3′ untranslated region (3′-UTR) of mRNAs, through Watson-Crick base
pairing postulate (Taby and Issa, 2010; Zhou et al., 2017). It is worth
mentioning that, miRNAs can function either as a promoter or a sup-
pressor to regulate the MDR of gastric cancers (Berindan-Neagoe et al.,
2014; Chen et al., 2018a,b). In gastric cancer, miRNAs including miR-
508-5p miR-15b, miR-27a, miR-200c, miR-181b, miR-16, miR-106a,
and miR-497, have been reported to be involved in MDR (Shang et al.,
2014; Gong et al., 2019). The human miR-29 family includes three
major members including miR-29a, b, and c. Transcriptional profiling
studies showed that miR-29 is down-regulated in the majority of can-
cers and up-regulated in the minority, which is miR-29a up-regulation
in colon cancer (Jiang et al., 2014). MiR-29a as a tumor suppressor
gene in several cancers can affect tumor cell growth invasion, migra-
tion, and apoptosis (Liu et al., 2018). Despite the development of the
biological function of miRNAs, the role of miRNAs in regulating drug
resistance in colon cancer remains under review.
Overall, our understanding of the physiologic and pathophysiologic
of colon cancer made possible by the elucidation of the signaling
pathways and related molecular disorders. In conclusion, we evaluated
effects of miR-29a on drug resistant in colon cancer cell with underlying
molecular mechanisms involved in MDR. For this purpose, we in-
vestigated the key role of miR-29a on P-gp as a member of ABC
transporters through PTEN/PI3K/Akt/MDR1/P-gp signaling pathway.
2. Materials and methods
2.1. Drugs and reagents
The human colon cancer cell line HT29 and DOX-resistant colon
cancer HT29/DOX cells were purchased from Pasteur Institute Cell
bank (Tehran, Iran); The miR-29a mimic and negative control were
obtained from microsynth AG (Balgach, Switzerland). DOX, PD098059,
LY294002, and verapamil were obtained from Cayman (USA). SF1670
was purchased from Echelon Biosciences Inc (USA). Lipofectamine
2000 purchased from Invitrogen. Rhodamine123 (Rh123), 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), propi-
dium iodide (PI), and RNase were purchased from Sigma (USA). Fetal
bovine serum (FBS) and Roswell Park Memorial Institute (RPMI) 1640
medium were purchased from Gibco (USA). Antibodies for P-gp, PTEN,
and β-actin were obtained from Abcam (Cambridge, UK).
2.2. Cell culture and transfection
HT29 and HT29/DOX Cell lines were cultured in the RPMI 1640
medium, supplemented with 10% FBS, 100 U/ml penicillin G and
100 μg/ml streptomycin at 37 °C in a humidified in 95% O2 and 5%
CO2 in a humidified incubator. HT29/DOX cells were seeded and cul-
tured in the presence of 0.5 μM of DOX or DOX free medium for two
weeks before being experiments. The sequence of the miR-29a mimic
was 5′ UAGCACCAUCUGAAAUCGGUUA 3′. Cells (5 × 105 cells/2 ml/
well) were seeded in six-well plates at 60% confluence. After 48 h, the
miR-29a mimic or the negative control was transfected into the cells
using Lipofectamine, at a final concentration of 50 nM, according to the
manufacturer's instructions.
2.3. MTT assay
The effect of DOX on cell viability in colon cancer cells growth was
performed with MTT assay. HT29 and TH29/DOX cells were plated
onto 96-well plates (2 × 104 cells/200μl/well) and incubated overnight
and transfected with miRNA-29a at 37 °C. Upon 24 h incubation, both
cell lines were treated with diverse concentrations of DOX to 48 h. Then
cells were treated with 10% MTT (5 mg/ml) for another 4 h. Following,
200 μl dimethyl sulfoxide (DMSO) was added to each well to dissolving
Fig. 4. Effect of miRNA-29a on the in-
tracellular accumulation of Rh123. Upon
culture for 48 h after transfection, the cells
were incubated with 5 μM of Rh123 in the
presence or absence of miRNA-29a, and its
inhibitor and 10 μM of verapamil for 2 h
and then, Rh123-associated MFI was mea-
sured. Each point depicts the mean ± S.D.
from four tests (*P < 0.05 compared con-
trol).
X. Shi, et al. European Journal of Pharmacology 880 (2020) 173138
3
formazan product. Then, absorbance values were measured at 450 nm
with a micro plate reader (State Fax 2100; Awareness Technology Inc,
USA) (Yan et al., 2019). The half maximal inhibitory concentration
(IC50) of each experiment was calculated. The fold reversal (FR) of MDR
was determined by dividing IC50 values of cells treated with the in-
dicated anticancer drug in the absence of a modulator by IC50 values of
cells treated with the same anticancer drug in the presence of a mod-
ulator.
2.4. RNA isolation and reverse transcription-polymerase chain reaction
(RT-PCR)
RNA was isolated from cells with AccuZolTM reagent, following the
manufacturer's instructions (Bioneer; Daedeok-gu, Daejeon, Korea).
Complementary DNA (cDNA) was synthesized using Moloney Murine
Leukemia Virus (MMLV) reverse transcriptase (Promega, Madison, WI).
Following qRT-PCR was performed using SYBR Premix Ex Taq (TaKaRa
Bio, Otsu, Japan) and specific primers via the Rotor-Gene™ 6000 system
(Corbett Life Science, Mortlake, Australia). PCR amplification was
performed at 95 °C for 3 min prior to 35 cycles of 95 °C for 30 s, 57 °C
for 30 s and 72 °C for 60 s, followed by a final incubation at 72 °C for
5 min. All experiments were carried out in triplicates. Raw data were
analyzed with the comparative Ct method using β-actin as a house-
keeping gene.
2.5. Western blot analysis
Proteins were extracted from cells using a lysis buffer containing
[20 mM Tris-HCl, 0.1% SDS, 1% Triton X-100, 150 mM NaCl, 1 mM
EDTA, 1 mM DTT, and pH 7.4,]. Then centrifuged at 14,000×g for
15 min at 4 °C. The protein concentration in the cell lysates was de-
tected by Bradford reagent with bovine serum albumin (BSA) as stan-
dard (Bio-Rad, USA). For western blotting, protein samples boiled with
SDS-PAGE loading dye and loaded at ~50 μg into each lane of PAGE
and separated by a SDS-PAGE gel. Proteins were transferred onto
polyvinylidene difluoride (PVDF) membranes, and the membrane was
then immersed in a blocking solution containing 5% BSA and 0.1%
Tween-20 in PBS for 1 h at room temperature with constant shaking.
Proteins were blotted with the primary antibodies at 4 °C overnight
with constant shaking. Upon washed three times in Tris-buffered saline
with 0.1% Tween 20 (TBST) at room temperature for 15 min, im-
munodetection was accomplished with incubation of secondary anti-
body conjugated with horseradish peroxidase (HRP) at room tempera-
ture for 2 h, followed by reaction with chemiluminescence HRP
substrate. Bands were identified using the enhanced chemilumines-
cence system (ECL) Western blot analysis Kit (Amersham Pharmacia
Biotech, Piscataway, NJ).
2.6. Assessment of P-gp activity
Rh123 operates as a good substrate for MDR-associated P-gp, and
drugs that inhibit P-gp have been found to enhance the retention of
Rh123 in MDR cells (Wang and Yang, 2008). To measure net Rh 123
uptake, 1 × 106 cells//2 ml/well were seed at 6-well plates. After 24 h
of incubation, cells were treated with medium containing 5 μM Rh123
in the presence or absence of miR-29a and were incubated at 37 °C for
2 h. Verapamil was used for P-gp inhibition. The intracellular mean
fluorescence intensity (MFI) associated with intracellular Rh 123 ac-
cumulation was measured using FP-6200 fluorometer (Jasco Co.,
Tokyo, Japan). Results were expressed in an arbitrary unit of the MFI.
Excitation was achieved by an argon-ion laser operating at 488 nm and
emitted at 530 nm.
2.7. Annexin V and propidium iodide (PI) staining
Cells were seeded at 1x106 cells/2 ml/well in 6-well plates, after
70% confluency incubated overnight and transfected with miRNA-29a
at 37 °C. After 24 h of treatment, the cells were washed twice with PBS.
Then incubated in the binding buffer (10 mM HEPES, 0.1% BSA,
140 mM NaCl, 2.5 mM CaCl2, and pH 7.4). In continue cell pellets were
suspended in 10 μl of fluorescein isothiocyanate (FITC)-labeled Annexin
V and PI solution for 10 min at dark in RT and then analyzed using a
fluorescence-activated cell sorting (FACS) flowcytometer (BD LSR;
Becton-Dickinson, USA) and Cell Quest software (Becton-Dickinson)
(Yan et al., 2019).
2.8. Statistical analysis
Statistical analysis was performed using mean ± standard devia-
tion (S.D.). Analysis of variance (ANOVA) followed by Bonferroni's and
Sidak's tests was used to ascertain the statically significant differences
Fig. 5. Effect of miRNA-29a on the P-gp expression. (A) P-gp protein expression
level (B) and MDR-1 mRNA expression in HT29 and HT29/DOX cells. Each
point represents the mean ± S.D. from four experiments (n = 3; *P < 0.05
compared control; #P > 0.05 compared control).
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between groups. P values lesser than 0.05 were considered to be stati-
cally significant. All statistical analyses were carried out with the
GraphPad Prism software version 6.01 (GraphPad, San Diego, CA).
3. Results
3.1. Effects of miR-29a overexpression on the viability of HT29 and HT29/
DOX cells
To investigate the possible role of miR-29a in the HT29/DOX colon
cancer cell, first, RT-qPCR analysis was performed. Results illustrated
that the expression level of miR-29a was higher in the HT29 cells
compared with the HT29/DOX cells (Fig. 1), which suggested that miR-
29a may be inversely associated with DOX-resistance in colon cancer
cells. Next, we assessed the effect of DOX on cell viability was de-
termined with the MTT assay. As shown in Fig. 2, DOX (concentration
range from 0.01 to 10 μM) displayed lower cytotoxicity towards the
MDR cells compared the corresponding parental cells, which caused
enhancement in the viability of HT29/DOX cells. The IC50 values for
DOX were 0.21 μM in HT29 and 2.84 μM in HT29/DOX cells, the latter
showing 13.52-fold resistance to DOX, compared to the HT29 cells.
3.2. miR-29a reversed MDR in HT29/DOX cells
To ascertain the correlation between miR-29a and HT-29a/DOX
cells, the effect of up-regulation and down-regulation of miR-29a on the
DOX-resistance cells was analyzed. The HT29 cells, which were treated
with the DOX, DOX + miR-29a mimic and DOX + miR-29 inhibitor
exhibited equal cytotoxicity in these cells (Fig. 3A). In contrast, the
HT29/DOX cells transfected with the DOX + miR-29a mimic and
Table 1
Cytotoxicity effect of DOX and reversing MDR in HT29/DOX cells role of miR-
29a and co-exposure with LY294002, PD098059, and SF1670 as selective in-
hibitors.
Treatment HT DOX
IC μM FR
29 /
50 ( )
Control (DOX) 2.84 ± 0.37 –
miR-29a + DOX 0.32 ± 0.09a 8.87
miR-29a + LY294002 10 μM + DOX 0.29 ± 0.08a,b 9.71
miR-29a + PD098059 10 μM + DOX 0.38 ± 0.08a,b 7.47
miR-29a + SF1670 10 μM + DOX 1.99 ± 0.31c 1.42
MTT reduction activity was used to determine cell viability. Each value re-
presents the mean ± S.D. of three independent tests. The fold reversal (FR) of
MDR was distinguished by dividing the IC50 of control to IC50 of each test.
Statically significant different from control at aP < 0.05; No significant dif-
ference from miR-29a + DOX group bP > 0.05; Significantly different from
miR-29a + DOX at cP < 0.05.
Fig. 6. PTEN inhibition abolished miR-29a effects on MDR. A) Intracellular Rh123 accumulation in HT29/DOX cells affected by miR-29a and specific inhibitors.
Treatment with 10 μM of LY294002 or PD098059 increased Rh123-associated MFI and with 10 μM of SF1670 almost abolished the effect of the miR-29a over-
expression. (B) P-gp protein expression and (C) MDR-1 mRNA in HT29/DOX cells 48 h after transfection. SF1670 suppress the effects of miR-29a. Data represent
mean ± S.D. (n = 3; *P < 0.05 vs untreated HT29/DOX cells).
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DOX + miR-29 inhibitor demonstrated statically significant lower and
higher survival rates than DOX group, respectively (Fig. 3B). In other
words, miR-29a overexpression can effectively reverse DOX resistance
in HT29/DOX cells, while down-regulation of this miRNA may play
critical role in the development of DOX resistance in HT29 cells.
3.3. miR-29a overexpression decreased P-gp activity
P-gp activity was determined using intracellular Rh123 accumula-
tion assay. Verapamil used as a positive control. Fig. 4 clearly demon-
strates that miR-29a enhances Rh123 accumulation in HT29/DOX cells
after 2 h, while HT29 cells showed no such enhancement when treated
with miR−29a. In addition, transfection of HT29/DOX cells with miR-
29a inhibitor resulted in the significant decrease in the accumulation of
Rh123 within these cells. Indeed, incubation of miR-29a-treated HT29/
DOX cells with the Rh123 resulted in the increase in the MFI
(P < 0.05). This effect comparable with that observed in HT29/DOX
cells treated with verapamil. Nevertheless, no accumulation of sub-
strate was recognized in parental HT29 cells over the same period.
Therefore, it was proposed that the activity of P-gp was inhibited via
miR-29a in HT29/DOX cells, and results from cells treatment with miR-
29a inhibitor approved this finding.
3.4. miR-29a down-regulated P-gp expression in HT29/DOX cells
In the present study, we expanded our work to a HT29/DOX cell line
to assess whether the observed effects were cancer cell type specific or
whether they might be more generally applicable. Western blot ana-
lyses using a P-gp-specific primary antibody showed that while the
HT29/DOX cells expressed significant amounts of P-gp, no P-gp was
detectable in the parental HT29 cells. These results strongly suggest
that the HT29/DOX cell line was phenotypically MDR and this MDR
phenotype was correlated to overexpression of P-gp (Fig. 5). We found
out that miR-29a down-regulated P-gp at the mRNA and protein levels
in HT29/DOX cells that can describe the elevated intracellular accu-
mulation of DOX and cytotoxicity in the miR-29a-treated HT29/DOX
cells. Moreover, treatment of DOX resistant cells with miR-29a inhibitor
led to significant overexpression of P-gp, as shown in Fig. 5.
3.5. PTEN inhibition abolished miR-29a effects on MDR
We speculated that miR-29a may play crucial role in the inhibition
of MDR1/P-gp expression by down-regulating PI3K/Akt signaling
pathway activity. Therefore, to further scrutinize the fundamental
molecular mechanisms, we investigated the MDR-reversing effect of
miR-29a in presence of special inhibitors of PI3K (LY294002), MAPK
(PD098059), and PTEN (SF1670). As shown in Table 1, compared with
the control group, DOX cytotoxicity was heightened in the miR-29a-
treated group. The IC50 values (μM) were diminished from
2.84 ± 0.37 to 0.32 ± 0.09, 0.29 ± 0.08, 0.38 ± 0.08, and
1.99 ± 0.31 in Control (DOX), miR-29a + DOX, miR-
29a + LY294002 10 μM+DOX, miR-29a + PD098059 10 μM+DOX,
miR-29a + SF1670 10 μM + DOX, respectively. However, miR-29a
effect was significantly attenuated by SF1670 treatment. Also, results
reveal that FR in miR-29a + SF1670 10 μM + DOX significantly dif-
ferent from miR-29a + DOX. Following culture for 48 h after trans-
fection with the miR-29a, the effect of LY294002, PD098059, and
SF1670 on the miR-29a-induced intracellular Rh123 associated MFI
accumulation was observed in HT29/DOX cells. Indeed, treatment with
10 μM of LY294002 or PD098059 enhanced Rh123-associated MFI and
with 10 μM of SF1670 almost abolished the action of the miR-29a
overexpression (Fig. 6A).
In this regard, our findings clearly demonstrated that miR-29a in
HT29/DOX cells 48 h after transfection attenuated P-gp protein ex-
pression and MDR-1 mRNA. Besides, SF1670 suppress the effects of
miR-29a (Fig. 6B and C). Moreover, further examinations showed that
in the presence of 10 μM of SF1670 eliminated miR-29a effects on P-gp
expression, while no similar effect with 10 μM ofLY294002 or 10 μM of
PD098059 was noted. Overall, these data illustrated that miR-29a-in-
duced down-regulation of the P-gp was associated with PTEN-depen-
dent manner in HT29/DOX cells.
3.6. miR-29a down-regulated P-gp via up-regulation of PTEN
To investigate the correlation between miR-29a and PTEN, PTEN
expression was evaluated in HT29/DOX cells treated with miR-29a and
its inhibitor. We revealed that PTEN expression was significantly lower
in HT29/DOX cells treated with miR-29a (Fig. 7A and B). More im-
portnatly, miR-29a inhibitor resulted in the up-regulation of PTEN in
HT29/DOX cells.
Fig. 7. PTEN is a direct target of miR-29a. Relative protein (A) and mRNA
levels (B) in HT29/DOX cells. The data represent mean ± S.D. (n = 3,
*P < 0.05 vs untransfected HT29/DOX cells).
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3.7. miR-29a promoted DOX-induced apoptosis in HT29/DOX cells
Flow cytometric analysis was performed to evaluate the impact of
HT29/DOX cells by Annexin V–FITC and PI staining, and apoptotic cells
were detected 48 h after miR-29a transfection. The lower right quad-
rant indicates the pro-apoptotic cell rate. We reveal that combination of
miR-29a with DOX enhanced the migration of HT29/DOX cells to
apoptotic regions as compared with DOX (Fig. 8). In addition, cells
treatment with miR-29a inhibitor could not exert significant effect in
increasing apoptosis in resistant cells.
4. Discussion
Our results showed three major findings, which allow us to a better
understanding of the role of miR-29a in colon cancer. 1) We have re-
vealed that miR-29a overexpression considerably inhibited the HT29/
DOX viability. 2) Our biological assays highlighted that miRNA-29a
significantly down-regulated P-gp expression in HT29/DOX cells and
alleviated drug resistance through elevation of intracellular DOX,
which reduced colon cancer cell growth. 3) We indicated that miR-29a
targets PTEN to inhibit drug resistance, proliferation, and apoptosis
through PI3K/Akt pathway. These biological findings have demon-
strated the critical role of miR-29a as a tumor suppressor in colon
cancer.
It is pivotal to identify unique strategies to enhance the effectiveness
of DOX for therapeutic purposes. Likewise, the enhancing popularity of
circulating miRNAs as a prognostic agent in cancer offers that these
molecules useful as non-invasive biomarkers to predict the patient re-
sponse to chemotherapy, which provides new insights about the func-
tional mechanism of MDR (Yang et al., 2015; Fruci et al., 2016). By
analyzing the cell index (CI; reflects the number of cells in each well)
identified more than 10 miRNAs that improve drug sensitivity when
overexpressed, which one striking example is miR-508-5p reversed
drug resistance most efficiently in gastric cancer. Shang et al. (Shang
et al., 2014) demonstrated that by targeting ABCB1 and ZNRD1, miR-
508-5p overexpression enhances the intracellular concentration of
chemotherapeutics and promotes drug-induced apoptosis in MDR gas-
tric cancer cells. In contrast, the results of the study on breast cancer by
Zhong and colleagues (Zhong et al., 2013) revealed that miR-222 and
-29a conferred DOX resistance in MCF-7 cells. The results of our study
showed that miR-29a was significantly down-regulated in HT29/DOX
cell line, compared with the parental HT29 colon cancer cell line. In-
deed, Overexpression of miR-29a in HT29/DOX cells causes restored
DOX-sensitivity and a significant decline in the viability of HT29/DOX
cells. Indeed, we sought to clarify that combination of miR-29a with
DOX enhanced the apoptosis of HT29/DOX cells compared with
HT29 cells.
Ameliorating chemo-sensitivity by targeting P-gp has been ex-
tensively used as a strategy for cancer therapy (Bao et al., 2012;
Majidinia et al., 2018; Majidinia et al. 2018a,b). The up-regulation of P-
gp in carcinoma cells elevated drug resistance, whereas inhibiting the
expression or function of P-gp was shown to reverse drug resistance.
These indicate defined the classical MDR associated role of P-gp (Tsuji
et al., 2012). In this regard, Zhao and colleagues (Bao et al., 2012)
revealed that miR-302 cooperatively sensitizes breast cancer cells to
DOX via repressing P-gp by targeting MAP/ERK kinase kinase1
(MEKK1) of ERK pathway. Also, Gao et al., (2016) showed that over-
expression of miR-145 sensitized breast cancer cells to DOX through
inducing intracellular DOX accumulation via inhibiting MRP1. PN and
colleagues (Yu et al., 2014) showed that down-regulation of miR-29
enhances cisplatin resistance in ovarian cancer cells. In this regard, our
results illustrate that miR-29a is capable of inhibiting the efflux of
Rh123 from HT29/DOX cells. On the other hand, incubation of miR-
29a-treated HT29/DOX cells with the Rho 123 resulted in the increase
in the MFI (Fig. 4). In fact, our data show that exposing resistant cells
with miR-29a can reverse MDR by increasing PTEN expression, in-
hibiting the P-gp activity, and enhancing the intracellular accumulation
of DOX, in HT29/DOX cells. Additionally, verapamil, a known P-gp
inhibitor, which enhances the intracellular retention of anticancer
agents in MDR cells (Ledwitch et al., 2016), enhance the Rho 123 ac-
cumulation in HT29/DOX cells, which is a positive control for valida-
tion of our results. With this perspective, present study results showed
that overexpression of miR-29a significantly decreased the activity as
well as the mRNA/protein expression levels of P-gp in HT29/DOX cells.
Moreover, inhibition of P-gp with specific inhibitor significantly en-
hanced the growth inhibition rate of the HT29/DOX cells, compared
with the control group. As a result, miR-29a sensitized HT29/DOX cells
to treatment with DOX.
Fig. 8. Apoptotic analysis of HT29/DOX cells by flow cytometry. Cells were stained with Annexin V–FITC and PI 48 h after transfection with miR-29a. Control (A),
miR-29a (B), miR-29a inhibitor (C) DOX, 0.5 μM (D), and miR-29a plus DOX, 0.5 μM (E).
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Besides, overexpression of PTEN in tumor cells has been associated
with the MDR-reversal effect and enhanced response of these cells to
chemotherapeutic agents by suppression of PI3K/Akt signaling pathway
(Chappell et al., 2011; Chen et al., 2018a,b; Mashayekhi et al., 2019;
Chen et al., 2020). The previous studies results show that PTEN as a
potential target of miR-29a. Indeed, PTEN as a tumor suppressor gene,
which acts as a direct target of miR-29a in the endothelium cells (Wang
et al., 2013). Du and colleagues (Du et al., 2016) revealed that miR-221
decreased gefitinib sensitivity via PI3K/Akt signaling pathway down-
stream of PTEN in human cervical cancer. Hernández et al. (Coronel-
Hernández et al., 2019) revealed that in colorectal cancer miR-26a is
significantly overexpressed, which means that miR-26a expression is
inversely correlated with PTEN. Moreover, miR-26a could directly in-
hibit PTEN expression via 3′ UTR interaction. Furthermore, Xie et al.,
(2018) revealed that treatment with miR-132/212 result in diminished
PTEN expression in MCF-7 cells in breast cancer. Inversely, we de-
monstrated that miR-29a a positive regulator of PTEN in improving
drug resistance in colon cancer. Wu et al., (2018) revealed that over-
expression of miR-503 leads to the sensitizer to cisplatin treatment in
ovarian cancer by targeting PI3K/p85. Furthermore, Han and collea-
gues (Mirza-Aghazadeh-Attari et al., 2018) reported that the protective
effects of miRNA-29a suppress the PTEN/Akt/GSK3β and Wnt/β-ca-
tenin signaling pathways in colon cancer. Also, Shen and colleagues
(Shen et al., 2016) demonstrated that down-regulation of miR-29a ex-
pression in MCF-7/DOX cells in breast cancer enhanced PTEN expres-
sion levels, resulting in diminished p-Akt and p-GSK3β expression
through PTEN/AKT/GSK3β signaling pathway. To our knowledge, we
show for the first time a positive regulation of PTEN exerted by miR-29a
in colon cancer cells. Surprisingly, we showed that PTEN expression
was statically significant lower in HT29/DOX cells, in fact, miR-29a
result in overexpression of PTEN in HT29/DOX cells. Up-regulation of
PTEN in these cells results in suppression of the PI3K/Akt signaling
pathway; in which finally, this mechanism results in the down-regula-
tion of P-gp and enhances drug accumulation in cells.
Taken together, this study has provided insight into the role of the
miR-29a/PTEN/PI3K/Akt/MDR1/P-gp axis in colon cancer drug re-
sistance. In this study, we recognized miR-29a as a novel MDR sup-
pressor through PTEN/PI3K/Akt/MDR1/P-gp pathway. These data
show that interference of miR-29a expression could be potentially
useful for the prediction of the clinical response to HT29/DOX, whereby
providing us a promising target for the therapy on colon cancer. Maybe
the results of this study can as an auxiliary bridge to future studies in
curative improving colon cancer patients.
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